Chikungunya virus (CHIKV) inhibitors from natural sources: a medicinal chemistry perspective by unknown
MINI-REVIEW
Chikungunya virus (CHIKV) inhibitors from natural sources:
a medicinal chemistry perspective
Soumendranath Bhakat1 • Mahmoud E. S. Soliman1
Received: 25 November 2014 / Accepted: 3 April 2015 / Published online: 29 April 2015
 The Japanese Society of Pharmacognosy and Springer Japan 2015
Abstract Chikungunya virus (CHIKV) is one of the re-
emerging ‘‘neglected’’ tropical diseases whose recent out-
break affected not only Africa and South-East Asia but also
several parts of America and Europe. To date, despite its
serious nature, no antivirals or vaccines were developed in
order to counter this resurgent infectious disease. The re-
cent advancement in crystallography and availability of
crystal structures of certain domains of CHIKV initiates the
development of anti-CHIKV agents using structure-based
drug design or synthetic medicinal chemistry approach.
Despite the fact that almost 50 % of the new chemical
entities against several biological targets were either ob-
tained from natural products or natural product analogues,
a very humble effort was directed towards identification of
novel CHIKV inhibitors from natural products. In this re-
view, besides a brief overview on CHIKV as well as the
nature as a source of medicines, we highlight the current
progress and future steps towards the discovery of CHIKV
inhibitors from natural products. This report could pave the
road towards the design of novel semi-synthetic derivatives
with enhanced anti-viral activities.
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Introduction
Chikungunya virus (CHIKV) is a re-emerging arbovirus
which belongs to the genus alphavirus and is responsible
for chikungunya fever (CHIKF), severe joint pains and
rash. The outbreak of CHIKF was first described in 1952
after an outbreak along the border of east African states,
Tanganyika and Mozambique. This mosquito born al-
phavirus is transmitted by mosquitoes of the Aedes genus
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Recent research highlighted the occurrence of A226 V
mutation in the envelope glycoprotein of CHIKV which
increased the CHIKV fitness in A. albopictus as well as
improved transmissibility of the virus through A. albopic-
tus [1]. In the mid twentieth century CHIKV emerged as a
major epidemic in India and South East Asia [1, 2]. After
several minor outbreaks in Africa, during 1999–2000 there
was a large outbreak of CHIKV in the Republic of the
Congo and further outbreak was documented in Gabon
through A. albopictus. The beginning of 20th century ob-
served a huge outbreak of chikungunya in India and several
islands of South-East Asia [1, 3]. Since 2005, India and
countries in South-East Asia have reported over 1.9 million
cases (Fig. 1b). In 2007, CHIKV transmission was reported
for the first time in Europe [4].
Recently the outbreak of chikungunya Caribbean island
was the first of its kind in the western hemisphere with 66
confirmed cases and suspected cases of around 181 [3]. By
the beginning of the year 2014 an estimated 30,000 cases
of CHIKV were confirmed in the Caribbean island which
brings the most alarming situation about the re-emerging
status of chikungunya [3]. Since then several cases of
CHIKV were documented in several parts of USA with an
alarming rate (Fig. 1a). This sudden re-emergence of
CHIKV across different parts of developed countries such
as USA led to a rising effort from academic research to
identify novel inhibitors targeting this re-emerging ne-
glected disease.
Nature as a source of medicines: a brief overview
Chemical constituents isolated from natural products
emerged as a source of novel therapeutics since early
stages of drug discovery. Statistically around 50 % of the
new chemical entities either obtained from natural products
or natural product analogues [5–9]. Several natural prod-
ucts and natural product analogues have been widely used
in a variety of different therapeutic indications, for in-
stance, a few examples are presented here (Fig. 2a, b).
Natural sources for medicines against tropical
diseases
The first spark of success was the discovery of the natural
compound artemisinin (Fig. 2c) to treat malaria, one of the
serious tropical diseases [11]. This was followed by a slow
but steady increase in natural product based inhibitors to-
wards re-emerging neglected tropical diseases especially
against malaria and dengue virus (DENV) [10] (Fig. 2d).
The natural product based treatment of malaria revolves
around discovery and development of novel analogs/
derivatives of highly active natural products e.g. sali-
nosporamide A, a marine actinomycetes with antimalarial
property, febrifugine and artemisinin [12]. The develop-
ment of natural product inspired medicinal chemistry ap-
proach led to development of halofuginone, as well as
some highly active febrifugine analogues as well as de-
velopment of novel artemisinin analogues [12]. Similarly,
several novel scaffolds were identified against different
serotypes of DENV by exploiting the pool of natural
products. This exploration led to identification of several
terpenoids, polycyclic quinones, phenolics, alkaloids, fla-
vonoids and polysaccharides against different serotypes of
DENV [10]. The success in identifying a diverse set of
natural product based scaffolds against DENV inspired the
progress of natural product based inhibitors in targeting
other neglected tropical diseases such as CHIKV.
Fig. 1 a Countries and territories where chikungunya cases have been reported (highlighted in green as of November 18, 2014) and b cases of
chikungunya outbreak during 1952–2006, the regions highlighted in ‘red’ have been reported with chikungunya outbreak during that period [3]
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To best of our knowledge this review is first of its kind
that highlights the current status in natural product based
inhibitors targeting CHIKV.
Structural biology of CHIKV
The genome of CHIKV is a positive sense, single stranded
RNA genome consists of two open reading frames, one in
50 end which encodes non-structural proteases necessary
for formation of viral replicase complexes and other 30 end
which encoded structural proteins, necessary for receptor
binding and fusion with cell membrane [1, 4, 13].
Despite the advancement in crystallography and struc-
tural biology, the rational drug discovery targeting several
domains of CHIKV genome were limited due to lack of
crystallographic evidences. The crystal structures of
CHIKV non-structural protease 2 (NSP2), non-structural
protease 3 (NSP3) macrodomain and immature envelope
glycoprotein complexes were resolved which emerged as a
promising starting point to develop novel inhibitors tar-
geting CHIKV [13].
Some of the recent reviews highlighted the detailed
features of CHIKV genome and its application in modern
era of antiviral drug discovery [1, 4, 13]. Herein, we em-
phasize on the structural features of CHIKV NSP2, NSP3
macrodomain and envelope glycoprotein complexes which
emerged as crucial drug targets to develop novel antivirals
targeting this re-emerging disease.
CHIKV NSP2 is responsible for protease and helicase
activity and thus emerged as a crucial target to develop
novel antivirals [1, 13]. Both N and C terminal domains are
composed of a-helices and b-strands. The active site of
CHIKV NSP2 is composed of residues located at C-ter-
minal domains. The active site (Fig. 3a) of NSP2 consists
of some key residues include Gln1039, Lys1045, Glu1157,
His1222, Cys1239, Ser1293, Glu1296 and Met1297
(Fig. 3b) [1]. CHIKV NSP2 is a cysteine protease thus
cysteine residues played an important role in enzyme ac-
tivity. Structural analysis of NSP2 showed the existence of
three N-terminal cysteine residues (Cys1013, Cys1057 and
Cys1121) as well three C-terminal cysteine residues
(Cys1233, Cys1274 and Cys1290). C-terminal cysteine
residues Cys1233 and Cys1290 in combination with his-
tidine residues (His1222, His1228, His1229 and His1236)
could be associated with deprotonation mechanism and
thus played a major role in viral pathogenesis [1].
Similar to NSP2, the crystal structure of N-terminal
domain of CHIKV NSP3 emerged as a potential drug target
to develop novel antivirals [15]. Advancement in crystal-
lography led to discovery of high resolution crystal struc-
ture of CHIKV NSP3 in complex with ADP ribose (Fig. 4)
[16]. NSP3 macrodomain believed to play a major role in
metabolism of ADP ribose derivatives that played major
role in cell regulatory function [1, 16]. Thus, understanding
the binding region of ADP ribose derivative could serve as
a starting point to develop novel inhibitors targeting
CHIKV [1].
Fig. 2 Some example of
natural products used in the
treatment of several diseases.
2D structures of several natural
product drugs used in the
treatment of cancer (paclitaxel,
a), hypertension (reserpine, b),
malaria (artemisinin, c).
Compound d [10] is one of the
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Similar to NSP3 macrodomain and NSP2, the mature
envelope glycoprotein complex comprises of E1-E2-E3
structural proteins [17] (Fig. 5) led to identification of two
plausible binding sites which might help in development of
novel anti-CHIKV agents targeting viral structural
proteins.
Till date, except the below-mentioned a few attempts
(Sect. ‘‘Natural products targeting CHIKV: a medicinal
chemistry perspective’’), a humble effort has been directed
rationally to design anti-CHIKV inhibitors targeting these
drug targets. Therefore, further natural products and natural
product-based optimization studies should be encouraged
in order to identify novel chemical entities targeting dif-
ferent structural/non-structural proteins of the ‘‘neglected’’
CHIKV.
Natural products targeting CHIKV: a medicinal
chemistry perspective
Despite the success of natural products as treatments for
various diseases like cancer [18, 19], malaria [20], and HIV
[21], the ‘‘neglected’’ CHIKV—and some others like
Sindbis virus (SINV)—has not received much attention
Fig. 3 Representation of
CHIKV NSP2 (PDB: 3TRK
[14]) which highlights the active
site region of NSP2 (represented
in green spheres, a as well as
critical residues of active site
are highlighted in orange (ball
and stick representation, b)
Fig. 4 Structure of CHIKV
NSP3 macrodomain in
complexed with ADP ribose
derivative (PDB: 3GPO [16],
a). The active site residues
interacting with NSP3 active
site might act as a foot print to
design novel chemical entities
targeting CHIKV NSP3
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from researchers. Herein, we compile the efforts that have
been made so far towards the identification of novel leads
from natural products that aimed to target CHIKV.
Recently the study of a Vietnamese plant species
Trigonostemon howii led to isolation of a new tigliane-type
diterpenoid, trigowiin A (1). Trigowiin A (1) (Fig. 6) ex-
hibited moderate antiviral activity in a virus-cell-based
assay against CHIKV. Antiviral testing of structurally
related tigliane diterpenoids such as prostratin (2), phorbol
(3), 12-O-tetradecanoylphorbol 13-acetate (TPA, 4), and
4a-TPA (5) (Fig. 6) led to identification novel antiviral
leads targeting CHIKV [22].
Besides the moderate CHIKV inhibitory activity pos-
sessed by trigowiin A, prostratin and TPA, two structurally
related tigliane-type diterpenoids, displayed potent and
selective anti-CHIKV activity (Table 1) [22]. The strong
inhibitory activity observed by prostratin (EC50 = 2.6 lM
and a selectivity index of 30) might initiate future efforts to
design optimized novel tigliane type diterpenoids-based
inhibitors since this chemical scaffold proved potential as
CHIKV inhibitor (Table 1) [22]. Bourjit et al. [22.] pos-
tulated that activation of the signal transduction enzyme
protein kinase C (PKC) could be the main reason behind
the antiviral activity of these molecules (compounds 1–5)
on CHIKV which is quite similar to the proposed
mechanism of TPA on HIV replication [23]. Thus the
structure and pharmacophoric features of these compounds
might be effective in order to develop specific PKC acti-
vators as potential anti-CHIKV agents.
In an effort to identify novel scaffolds targeting CHIKV
replication, an extensive study taking in account 820 ethyl
Fig. 5 The mature glycoprotein complex of CHIKV (PDB: 3N42
[17]) which might act as a promising target to develop novel drug
molecules targeting CHIKV structural proteins
Fig. 6 2D structural
representation of tigliane-type
diterpenoids trigowiin A (1)
prostratin (2), phorbol (3),
12-O-tetradecanoylphorbol
13-acetate (TPA, 4), and 4a-
TPA (5)
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acetate extracts of Madagascan plants was performed in a
virus-cell-based assay for CHIKV. This exploration led to
identification of one new(E)-tridec-2-en-4-ynedioic acid
named anacolosine (6), together with three known acet-
ylenic acids, the octadeca-9,11,13-triynoic acid (7), (13E)-
octadec-13-en-9,11-diynoic acid (8), (13E)-octadec-13-en-
11-ynoic acid (9), two terpenoids, lupenone (10) and b-
amyrone (11), and one cyanogenic glycoside, (S)-sam-
bunigrin (12) (Fig. 7) [24].
The inhibitory activity of these chemical entities was
tested against CHIKV in a viral cell-based assay. Two
terpenoids, lupenone (10) and b-amyrone (11) displayed
moderate inhibitory activity against CHIKV with EC50
77 lM and 86 lM, respectively (Table 2) [24]. The in-
hibitory effect of lupenone (10) further confirmed that lu-
pane based triterpenoid skeleton are selective inhibitors of
CHIKV and can be further optimized in order to provide
semi-synthetic derivatives with enhanced anti-viral
activity.
Further, bioassay guided purification and virus cell-
based assay of an EtOAc extract of the leaves of Croton
mauritianus led to isolation of two phorbol esters 12-O-
decanoylphorbol-13-acetate and 12-O-decanoyl-7-hy-
droperoxy-phorbol-5-ene-13-acetate as well as five ionone
derivatives i.e. loliolide, vomifoliol, dehydrovomifoliol,
annuionone D and bluemol C [25]. Virus cell based assay
identifies 12-O-decanoylphorbol-13-acetate (13) and 12-O-
decanoyl-7-hydroperoxy-phorbol-5-ene-13-acetate (14)
(Fig. 8) as novel inhibitors of CHIKV with EC50 of
2.4 ± 0.3 lM and 4.0 ± 0.8 lM, respectively [25]. Ex-
ploring the inhibitory effect of structural analogues of these
phorbol esters and side chains associated with the main
skeleton might act as an area of further exploration to
target CHIKV.
Moreover, A study has been performed on the bark and
the wood of a rare endemic plant Trigonostemon cherrieri
led to isolation of highly oxygenated daphnane diter-
penoid orthoesters (DDO) bearing an uncommon chlori-
nated moiety: trigocherrins A (15), B (16) and F (17)
(Fig. 9) and trigocherriolides A (18), B (19) and C (20)
(Fig. 9) displayed moderate to fair activity against
CHIKV with EC50 ranging from 1.5 to 3.9 lM [26].
Trigocherrins B was identified as the most active diter-
penoid with EC50 1.5 lM against CHIKV in a virus cell
based assay (Table 3) [26]. These DDOs further pos-
sessed significant inhibitory activity against several other
neglected re-emerging pathogens including Sindbis virus
(SINV), Semliki forest virus (SFV) and DENV and thus
can be explored further to design novel leads targeting
several re-emerging viruses.
In another study, the aqueous-ethanolic and ethanolic
extracts of the leaves of Vitex negundo, Hyptis suaveolens
and roots of Decalepis hamiltonii were studied for their
antiviral activity against CHIKV. The extracts were found
to be effective against Asian strain of CHIKV with an IC50
of 15.62 lM [27]. This study led to an interesting finding
as the aqueous ethanolic extract of Hyptis suaveolens found
to be more selective towards inhibition of Asian strain of
CHIKV when compared with ribavirin. This inhibitory
activity might be due to the presence of pentacyclic
triterpenoids as major constituent. Further study might
focus on purification of active constituents to explore novel
scaffolds with antichikungunya activity.
In a recent study, an immunofluorescence-based
screening was performed to identify potential inhibitors of
CHIKV using a highly purified natural product compound
library. Out of these focused library 44 compounds ex-
hibiting[70 % inhibition of CHIKV infection were iden-
tified as positive hits. Harringtonine (21), (Fig. 10), a
cephalotaxine alkaloid, displayed an EC50 0.24 lM with
minimal cytotoxicity [28]. In addition to its potent anti-
CHIKV activity, time-of-addition studies, cotreatment as-
says etc. highlighted that harringtonine inhibit an early
stage of CHIKV replication cycle by affecting viral protein
expression [28]. The highly selective inhibitory nature of
harringtonine as well as its inhibitory activity against
sindbis virus, another alphavirus makes it a blockbuster
candidate for further rational drug design efforts against
CHIKV and other alphaviruses.
CHIKV NSP2 (non-structural protease 2) is one of the
emerging target to discover novel inhibitors towards this
emerging alphavirus. High throughput screening of 3040
molecules led to identification of a natural compound (22),
(Fig. 11) which partially blocks NSP2 and CHIKV repli-
cation [29]. This study could further open up an opportu-
nity to develop novel CHIKV NSP2 inhibitors from a
natural product.
Also recently, a focused library of 356 compounds in-
cluding natural products and clinically approved drugs were
screened against EGFP and Rluc marker genes expressed by
the CHIKV replicon. The 5, 7-dihydroxyflavones apigenin
Table 1 Antiviral activities of compounds 1–5 in vero cells against
CHIKV [22]
Compounds CC50 vero cells (lM) EC50 CHIKV (lM)
Compound 1 [100 43.5 ± 12.8
Compound 2 79.0 ± 17.4 2.6 ± 1.5
Compound 3 [343 [343
Compound 4 5.7 ± 1.7 0.0029 ± 0.0003
Compound 5 5.3 ± 0.6 2.8 ± 0.5
456 J Nat Med (2015) 69:451–462
123
(23), chrysin (24), naringenin (25) and silybin (26) (Fig. 12)
were found to suppress activities of EGFP and Rluc (Renilla
luciferase) marker genes expressed by the CHIKV replicon
(Table 4) [30]. Further these compounds also found to in-
hibit genome-replication of Semliki Forest virus (SFV),
another alpha virus. Silybin (28) found to inhibit the entry
of SFV into the host cell [30]. The antiviral activity of these
compounds on Rluc gene confirmed that these molecules
can inhibit genome replication of CHIKV and other al-
phaviruses [30]. Thus development of small molecule in-
hibitors using the pharmacophoric features of these
Fig. 7 Structural representation
of anacolosine (6), octadeca-
9,11,13-triynoic acid (7), (13E)-
octadec-13-en-9,11-diynoic acid
(8), (13E)-octadec-13-en-11-
ynoic acid (9), lupenone (10), b-
amyrone (11), and (S)-
sambunigrin (12)
Table 2 Antiviral activities of compounds 6–12 in vero cells against
CHIKV [24]
Compounds CC50 vero cells (lM) EC50 CHIKV (lM)
Compound 6 [420 [420
Compound 7 30 [30
Compound 8 23 [23
Compound 9 30 [30
Compound 10 [235 77 ± 26
Compound 11 [235 86 ± 9
Compound 12 [426 [426
J Nat Med (2015) 69:451–462 457
123
compounds might lead to development of new replication
inhibitor against CHIKV. Whereas, the structural and
pharmacophoric feature of silybin (28) will be helpful in the
development of entry inhibitors targeting CHIKV and other
alphaviruses.
In a different report, two new daphnane diterpenoid
orthoesters, trigocherrierin A (27), (Fig. 13) and
trigocherriolide E were isolated from the leaves of
Trigonostemon cherrieri exhibited anti-CHIKV activity in
virus cell-based assay [31]. Trigocherrierin A displayed
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strongest anti-CHIKV activity with EC50 0.6 ± 0.1 lM
and selectivity index (SI) = 71.7 [31].
In another unique study, bioassay guided purification of
an EtOAc extract of the whole plant of Euphorbia
amygdaloides ssp. semiperfoliata led to identification of a
new jatrophane ester (38), (Fig. 14) which exhibited po-
tent and selective inhibitory activity against CHIKV with
an EC50 of 0.76 lM [32]. Findings reported from this
exploration can be further continued with structure ac-
tivity relationship study to develop more potent anti-
CHIKV inhibitors by providing correct substitutions on
the jatrophane skeleton.
Epigallocatechin-3-gallate (EGCG) (29), (Fig. 15), one
of the major component of green tea displayed several
biological activities such as HIV [33], cancer [34], fatigue
syndrome [35] etc. Recent antiviral examination of EGCG
displayed antiviral activity of EGCG against CHIKV.
EGCG inhibited CHIKV infection in vitro by blocking the
entry of CHIKV Env-pseudotyped lentiviral vectors and
inhibiting CHIKV attachment [36]. Thus EGCG might be
used as a structural template to design potent small mole-
cule inhibitors targeting CHIKV.
Another antimalarial natural product, quinine (30),
(Fig. 16) displayed significant anti-CHIKV activity with an
IC50 0.1 lg/ml at a concentration less than chloroquine
(IC50 = 1.1 lg/ml) [37].
As a closing remark, the current efforts made to identify
novel natural products against CHIKV is still insufficient
and further research is highly encouraged towards either
the discovery of novel leads or optimization of the cur-
rently identified compounds. This report demonstrated
various potential chemical entities/scaffolds from natural
sources; such information could assist medicinal chemists
towards the design of optimized and more potent inhibitors
against CHIKV.
Conclusions
During last 3 years, exploring several natural products as
potential antivirals targeting CHIKV has gradually in-
creased. Several interesting scaffolds with moderate to
potent activity against CHIKV were reported, however, due
to the neglected nature of the disease, less efforts were
reported in order to optimize novel scaffolds identified
from natural products in order to develop potent and se-
lective inhibitors with an increased potency and ADME
profile. Furthermore, the majority of the inhibitors were
identified using in vitro cell-based assays, hence, identifi-
cation of enzyme specific inhibitor targeting CHIKV is still
a major challenge. As a result, till date, a very small
amount of chemical space containing natural products have
been explored in order to identify potent anti-CHIKV
agents. With the advancement in assay techniques, future
efforts might be directed towards identification of novel
anti-CHIKV agents targeting specific structural/non-struc-
tural proteins using novel scaffolds identified from natural
products. Natural product inspired small molecule in-
hibitors might prove a cornerstone in the hectic develop-
ment process of drug candidates against CHIKV due to














Fig. 10 Structural representation of harringtonine (21), a cephalotax-
ine alkaloid which displayed significant inhibitory activity against
CHIKV [28]
Table 3 Anti-CHIKV activities of compounds 15–20 in virus cell
based assay [26]
Compounds CC50 vero cells (lM) EC50 CHIKV (lM)
Compound 15 35 ± 8 1.5 ± 0.6
Compound 16 93 ± 3 2.6 ± 0.7
Compound 17 23.1 ± 0.6 3.0 ± 1.2
Compound 18 4.6 ± 0.8 1.9 ± 0.6
Compound 19 5.3 ± 0.2 2.5 ± 0.3
Compound 20 10.5 ± 0.1 3.9 ± 1.0
Fig. 11 Chemical representation of compound 22 which displayed
inhibitory activity against CHIKV NSP2 [29]
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computational approach the structural and pharmacophoric
features of active natural products can be used in order to
develop target specific inhibitors against CHIKV. The use
of GRID computing and collaborative drug discovery ef-
forts will play a crucial role in this process in order to
speed up the discovery process. In conclusion, more effort
from researchers towards the development of antiviral
agents targeting CHIKV from natural products is highly
Fig. 12 2D structural
representations of compound
23-26 which displayed antiviral
activities against EGFP and
Rluc marker genes expressed by
the CHIKV [30]
Fig. 14 Structural representation of a jatrophane ester (28) which
exhibited selective inhibitory activity against CHIKV [32]. ‘‘R’’
represents tiglyloxy (Tig) group
Table 4 Antiviral activity of compound 25–28 against EGFP and
Rluc marker genes expressed by the CHIKV [30]
Natural products EGFP IC50 (lM) Rluc IC50 (lM)
Apigenin (23) 22.5 28.3
Chrysin (24) 46.8 50.2
Naringenin (25) 25.8 30.0
Silybin (26) 71.1 59.8
Fig. 13 2D structural representation of daphnane diterpenoid orthoe-
ster based CHIKV inhibitor, trigocherrierin A (27) [31]
Fig. 15 2D structural feature of epigallocatechin-3-gallate (29)
460 J Nat Med (2015) 69:451–462
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encouraged. More advanced computer-assisted and mole-
cular modelling approaches augmented with analytical and
experimental techniques should be applied in order to op-
timize the activity of the currently discovered natural
compounds.
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